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Abstract 
Background: Induction chemotherapy by isolated limb perfusion (ILP) with melphalan and tumour necrosis factor‑α 
is an effective strategy to facilitate limb‑conserving surgery in locally advanced extremity sarcoma. In a comparison of 
cohorts matched for grade, size and surgical resectability, we compared the outcome of patients undergoing induc‑
tion ILP prior to limb‑conserving surgery and selective post‑operative radiotherapy with patients undergoing limb‑
conserving surgery and routine post‑operative radiotherapy.
Methods: Patients with primary, grade 2/3 sarcomas of the lower limbs over 10 cm in size were identified from 
prospectively maintained databases at 3 centres. Patients treated at a UK centre underwent limb‑conserving surgery 
and post‑operative radiotherapy (Standard cohort). Patients at two German centres underwent induction ILP, limb‑
conserving surgery and selective post‑operative radiotherapy (ILP cohort).
Results: The Standard cohort comprised 80 patients and the ILP cohort 44 patients. Both cohorts were closely 
matched in terms of tumour size, grade, histological subtype and surgical resectability. The median age was greater 
in the Standard vs the ILP cohort (60.5 years vs 56 years, p = 0.033). The median size was 13 cm in both cohorts. 5‑year 
local‑recurrence (ILP 12.2%, Standard 20.1%, p = 0.375) and distant metastases‑free survival rates (ILP 49.6%, Standard 
46.0% p = 0.821) did not differ significantly between cohorts. Fewer patients received post‑operative radiotherapy in 
the ILP cohort compared with the Standard cohort (27% vs 82%, p < 0.001).
Conclusion: In comparative cohorts, the outcomes of patients undergoing induction ILP prior to surgery did not 
differ from those undergoing standard management, although induction ILP was associated with a reduced need for 
adjuvant radiation.
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Background
Extremity soft tissue sarcomas (ESTS) are rare tumours 
comprising over 50 different histological subtypes [1, 2]. 
Optimal management of locally advanced ESTS requires 
multimodal therapy and the precise role of isolated limb 
perfusion (ILP) in the overall treatment strategy remains 
to be fully defined. For small or superficial ESTS, treat-
ment usually involves surgery alone, gaining wide sur-
gical margins while preserving function. Adjuvant 
radiotherapy is reserved for high-grade tumours greater 
than 5 cm or small tumours that focally involve margins 
adjacent to a critical structure [3]. When sarcomas attain 
even greater dimensions, such as over 10 cm, it becomes 
increasingly difficult to achieve negative margins with-
out recourse to amputation or function-limiting surgery. 
While amputation for ESTS does not improve survival 
for sarcoma over limb-conserving surgery, it may still 
be considered for large sarcomas when the risk for local 
recurrence is viewed as significant [4–6].
Induction chemotherapy by ILP using melphalan 
with recombinant human tumour necrosis factor alpha 
(TNFα) prior to a limb-conserving surgical resection 
was introduced as a strategy for locally advanced sar-
comas considered irresectable other than by an ampu-
tation [7]. TNFα is a multifunctional cytokine, which 
causes increased vascular permeability, associated with 
increased extravasation of cytotoxic agents and selective 
destruction of tumour-associated vessels by endothelial 
apoptosis and inflammation [8–10]. A multi-institutional 
case series of patients with locally advanced sarcomas, 
considered to be irresectable with limb-conserving sur-
gery and adjuvant radiotherapy, which were treated using 
ILP with TNFα reported a limb salvage rate of 84% [7]. 
In light of these results, TNFα has been licensed for this 
indication since 2006.
ILP is now used more widely in large, high-grade 
tumours that are compatible with limb-conserving sur-
gery but risk positive resection margins. Such patients 
would undergo an induction ILP prior to a wide resection 
of the primary tumour, with the aim of gaining as wide 
a margin as is compatible with preserving limb function. 
Post-operative radiotherapy is then typically only offered 
if the pathology specimen demonstrates viable tumour 
at a compromised margin. The alternative, which might 
be considered the standard management, would be a 
function-preserving wide resection with adjuvant radio-
therapy to compromised margins. It is known that with 
adjuvant radiotherapy, planned microscopic positive 
margins over a critical structure are fully compatible with 
long-term local control [11].
In a retrospective cohort analysis, we sought to 
determine whether the peri-operative morbidity and 
oncological outcomes differed between these alternative 
multi-modality approaches to large high-grade sarcoma 
of the lower limb.
Patients and methods
Patient selection
Patients were identified from 1996 to 2010 using pro-
spectively maintained databases at the Royal Marsden 
Hospital London, UK (defined as the Standard cohort) 
and the Sarcoma Center Berlin-Brandenburg and the 
University Medical Center Mannheim, Germany (defined 
as the ILP cohort). In the ILP cohort, all patients with a 
primary, unifocal, intermediate or high-grade (G2 and 
G3) ESTS of the lower limb with a maximum dimension 
of over 10  cm who underwent an induction ILP prior 
to a surgical resection were included. In the Standard 
cohort, all patients with the same characteristics but who 
had undergone limb-conserving surgery were included. 
Patients with disseminated disease at diagnosis or who 
had received pre-operative systemic chemotherapy were 
excluded.
Grading was according to the FNCLCC system [12]. 
Each tumour was staged as T2b N0 MO G2 or G3, corre-
sponding to stage IIb or III in the AJCC system [13]. Size 
was defined by pre-operative cross sectional imaging (CT 
or MRI) and confirmed after pathological analysis. The 
administration of adjuvant radiotherapy in either cohort 
was not an inclusion criterion and all decisions relating 
to radiotherapy were made on an individual patient basis.
Treatment
The ILP cohort underwent induction ILP with TNFα 
(Beromun™, Boehringer Ingelheim, Germany) and mel-
phalan followed by a wide or compartmental resection 
of the tumour 6–10 weeks later. Adjuvant radiation was 
not given routinely but considered in case of R1 resec-
tions or where the rate of necrosis post-ILP was consid-
ered suboptimal. The Standard cohort underwent a wide 
or compartmental resection, with radiotherapy offered at 
6–12 weeks post-operatively [14].
Isolated limb perfusion
ILP has been described in detail before [7]. The proce-
dure was performed under general anaesthesia. The per-
fusions were hyperthermic, with a target temperature of 
38–39.5  °C. TNFα was administered after a stable limb 
circuit without leakage had been established, at a dose of 
2–4 mg. Melphalan was applied 15 min later, at a dose of 
10  mg/L of perfused limb volume. Total perfusion time 
was 90 min. The extremity was then rinsed with hydroxyl 
ethyl starch.
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Surgical resection
The surgical approach in both cohorts was to achieve 
negative surgical histopathological margins where pos-
sible in the context of a limb-conserving operation. En-
bloc resections with wide margins (1–2 cm of uninvolved 
tissue or an intact adjacent fascial layer) were performed 
whenever possible. When the tumour abutted major ves-
sels or motor nerves, the adventitia or epineurium was 
taken as the margin of resection. When vessels were 
encased, they were resected and reconstructed. When 
the tumour abutted the bone, the periosteum was taken 
en-bloc with the tumour. Soft tissue reconstruction 
with pedicled or free-flaps was performed whenever 
necessary.
Adjuvant radiotherapy
Post-operative radiotherapy was administered 
6–10  weeks post-surgery. In the Standard cohort, post-
operative radiotherapy was considered for all cases. How-
ever, the final decision was made by a multi-disciplinary 
team in light of post-operative histology, the surgical 
margins and the patient’s age and co-morbidities. In the 
ILP cohort, radiotherapy was administered in selected 
cases when there was a suboptimal histopathological 
response (less than 90% necrosis or viable tumour pre-
sent at a surgical margin).
Histopathological analysis
Histopathologic analysis included assessment of resec-
tion margins and pathological response. A macroscopi-
cally positive margin was defined as R2 resection. If the 
tumour extended into the resection margin (< 1 mm) on 
microscopic examination, the margin was defined as R1 
resection and margins without actual involvement of the 
resection margin (> 1 mm or an intact fascial plane) were 
considered microscopically negative (R0).
Follow‑up
Patients were followed up every 3–4 month intervals for 
the first 3 years, then twice a year for up to 5 years, and 
annually thereafter.
Cohort comparison for resectability
To ensure that the tumours in both cohorts were equiva-
lent in terms of resectability, three independent sarcoma 
surgeons working at major European sarcoma centres 
reviewed anonymised MRI’s from patients within each 
cohort and scored the compatibility of the tumours with 
limb-conserving surgery and adjuvant radiotherapy 
alone. Twenty patients were randomly selected from 
each cohort. The anonymised images, together with basic 
patient details (gender, age, histopathology and tumour 
size), were then distributed to the assessors who ranked 
the images based on resectability from 1 to 10, with 1 
being easily resectable by limb-conserving surgery and 
10 indicating that limb conservation was impossible and 
amputation was required (Fig. 1).
Statistical analysis
To identify risk factors for local recurrence, metastasis 
and death from disease, stepwise Cox proportional-haz-
ards regression analyses were performed using SPSS ver-
sion 20. The influence of age (< 65 vs. ≥ 65 years), tumour 
size, tumour grade (2 vs. 3), resection margin (R0 vs. R1), 
post-operative irradiation (yes vs. no), and local recur-
rence were assessed. Overall survival, systemic and local 
recurrences were calculated using Kaplan–Meier method 




Details of patient demographics are shown in Table  1. 
80 patients were identified in the Standard cohort and 
compared to 44 patients in the ILP cohort (Fig.  2). The 
median age of patients in the Standard cohort was 
60.5  years (range 18–92), which was significantly older 
than the ILP cohort with a median age of 56 years (range 
17–82), (Mann–Whitney test p = 0.033). There was no 
difference in tumour size between the two cohorts with 
both having a median tumour size of 13  cm (Standard 
range 10–29, ILP range 10–34), (p = 0.915 Mann–Whit-
ney test). The proportion of grade 2 and 3 tumours was 
also similar with the Standard cohort having 52 (65%) 
of patients with grade 3 tumours and the ILP cohort 31 
patients (70.5%) (p = 0.840 Fisher’s exact test). No sig-
nificant difference was found in the score of resectability 
between the two groups (Standard Cohort vs ILP median 
4.45 vs 5.05 p = 0.314, mean 5.12 vs 4.23 p = 0.112) 
although the ILP cohort had slightly higher absolute 
scores (Additional file 1: Figure S1).
Treatment
Details of operative characteristics, complications, resec-
tion margins, final tumour histology and follow-up are 
shown in Table  2. Patients in the ILP cohort were sig-
nificantly more likely to undergo vascular reconstruction. 
The use of flaps was also more common in this cohort. 
No significant difference in significant complications, 
defined as wound infections or collections requiring sur-
gical or radiological intervention, was noted between the 
two cohorts. Two patients (5%) in the ILP cohort required 
an amputation. One amputation was performed in the 
peri-operative period due to procedure-related complica-
tions. The other amputation was performed 18  months 
after surgery due to chronic ulceration following a 
Page 4 of 9Jakob et al. Clin Sarcoma Res  (2018) 8:12 
wound infection. No patients in the Standard cohort 
required amputation. In the Standard cohort 66 (82%) of 
patients received adjuvant radiotherapy compared to 12 
(27%) patients in the ILP cohort (p < 0.001, Chi square). 
The reasons for omitting radiotherapy in the Standard 
cohort were age and associated performance status (4 
patients, median age 87.3 years), a compartmental resec-
tion achieving negative margins in all planes (6 patients, 
median age 57.7 years) or the rapid development of pul-
monary metastases in the early post-operative period (4 
patients). In the ILP cohort, the local recurrence rate in 
patients not receiving adjuvant radiotherapy was not sig-
nificantly different to those who did (12.5% vs 8%, p = 1.0 
unpaired t-test).
Oncological Outcomes
The median follow-up for the Standard and ILP cohorts 
was 31 (4–194) months and 36 (8–163) months, respec-
tively. The 5-year local recurrence-free (ILP cohort 12.2%, 
Standard cohort 20.1%, p = 0.375 log-rank test) and dis-
tant metastases-free survival (ILP cohort 49.6%, Standard 
cohort 46.0%, p = 0.821 log-rank test) did not signifi-
cantly differ between cohorts (Fig. 3). Furthermore, at the 
time of writing, the local failure rate (i.e. patients devel-
oping local recurrence or requiring amputation) for both 
treatment arms was identical at 16%. Treatment strategy 
was not predictive of local or distant recurrence, with the 
only factors found to increase the risk of local recurrence 
on multivariate analysis being age and a positive (R1) 
resection margin (Table  3). The 5-year overall survival 
was worse in the Standard cohort compared to the ILP 
cohort (46.8% vs 63.8%, p = 0.020 log-rank test). How-
ever, in a Cox proportional hazard model, when the dif-
ferences in age between the two cohorts were accounted 
for, the overall survival on multivariate analysis between 
the ILP and Standard cohorts was virtually identical (HR 
1.02, 95% CI 1.00–1.04, p = 0.043).
Fig. 1 Examples of MRI imaging of patients used for comparison of tumour resectability in cohorts
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Discussion
Standard treatment for locally advanced ESTS consists 
of limb-conserving surgery with adjuvant radiotherapy 
that may be delivered pre or post-operatively [15]. The 
role of (neo)adjuvant chemotherapy outside of specific 
chemo-sensitive subtypes in ESTS is controversial. In the 
EORTC 62931 study, Woll et al. randomised patients with 
localised, grade II or III extremity sarcoma to receive 
adjuvant cheomotherapy in the form of doxorubicin, ifos-
famide and lenogastrim in addition to surgery, radiother-
apy and, if appropriate, ILP [16]. No benefit in terms of 
relapse-free or overall survival with this adjuvant regime 
compared to the control cohort were identified (5-year 
OS 66.5% vs 67.8%). More recently, in the ISG-STS 1001 
study, Gronchi et al. randomised patients with localised, 
high-grade extremity sarcoma of 5 specified subtypes 
to receive neoadjuvant standard chemotherapy, in the 
form of epirubicin and ifosfamide, or histotype-tailored 
regimes [17]. This trial closed early after an interim anal-
ysis demonstrated no benefit in the histotype-tailored 
regimes. However, at 48  months, overall suvrival in the 
standard cohort was 89%, which suggests a potential ben-
efit to neoadjuvant standard chemotherapy in these his-
tological subtypes. As of yet, there is consensus regarding 
the role of (neo)adjuvant chemotherapy and its use is not 
considered standard in the most recent guidelines [18]. In 
contrast, induction chemotherapy with ILP is widely rec-
ognised to produce markedly better response rates than 
systemic chemotherapy and has a well-established role 
in facilitating function-preserving resections in locally 
advanced ESTS that would otherwise require amputation 
[7, 19–24].
With induction ILP increasingly used for ESTS that may 
be amenable to standard surgical management, the ques-
tion as to which strategy, if either, is superior has arisen. 
Previous case series have clearly shown that induction 
ILP prior to surgery is an effective approach to deal with 
compromised surgical margins, as wide surgical resec-
tions were not possible. Similarly adjuvant radiotherapy 
has been shown to be effective in preventing local relapse 
after positive surgical margins [25]. The ability to directly 
compare these treatment strategies is hampered by the 
rarity of locally advanced non-metastatic primary ESTS 
and the scarcity of specialist centres performing ILP. As 
such, a randomized study comparing these strategies is not 
feasible [26]. Although subject to the limitations of any ret-
rospective study, this comparison of matched cohorts pro-
vides valuable evidence to compare these two approaches.
The present study has found that the peri-operative and 
oncological outcomes of patients undergoing induction 
ILP prior to surgical resection are very similar to those 
undergoing standard surgical management. No signifi-
cant difference was found in the rate of peri-operative 
complications between cohorts. Although two patients in 
the ILP cohort required amputations, only one was due 
to procedure-related complications. Similarly, no signifi-
cant difference was found in the rates of local recurrence 
between these treatment arms, despite the use of adju-
vant radiotherapy being significantly less frequent in the 
ILP cohort. There are no clear guidelines regarding the 
use of radiotherapy following ILP, although it is typically 
considered following an inadequate response on histo-
logical assessment of the specimen. However, following a 
microscopically complete resection with over 50% necro-
sis in the specimen, adjuvant radiotherapy is unlikely to 
be of additional benefit [27].
As a retrospective study, this series is subject to the 
bias inherent with this methodology. However, analysis 
of the tumour characteristics in terms of grade, size and 
histological subtype showed that the cohorts were well 
matched and this is reflected in the identical rate of met-
astatic spread. Similarly the assessment of the tumours 
“resectability” by independent experts indicated that the 
technical difficulty of surgery appeared to be similar in 
both cohorts. Although the cohorts were reasonably well 
matched, they were not randomized and we identified 
some important differences. There was a higher propor-
tion of popliteal fossa and leg tumours in the ILP cohort. 
It is generally accepted that achieving local control for 
Table 1 Patient and tumour characteristics
MPNST malignant peripheral nerve sheath tumour
Standard cohort ILP cohort Overall
Number of patients 80 44 124




 Male 46 (57.5%) 24 (54.5%) 70 (56.5%)
 Female 34 (42.5%) 20 (45.5%) 54 (43.5%)
Tumour site
 Thigh 74 (92.5%) 30 (68.2%) 104 (83.9%)
 Popliteal fossa 1 (1.3%) 5 (11.4%) 6 (4.8%)
 Leg 5 (6.3%) 9 (20.5%) 14 (11.3%)
Median tumour size (cm) 13 13 13
Tumour grade
 II 28 (35.0%) 13 (29.5%) 41 (33.1%)
 III 52 (65.0%) 31 (70.5%) 83 (66.9%)
Histology
 Pleomorphic 35 (43.8%) 20 (45.5%) 55 (44.4%)
 Liposarcoma 13 (16.3%) 10 (22.7%) 23 (18.5%)
 Leiomyosarcoma 9 (11.3%) 5 (11.4%) 14 (11.3%)
 Solitary fibrous tumour 3 (3.8%) 1 (2.3%) 4 (3.2%)
 MPNST 2 (2.5%) 2 (4.5%) 4 (3.2%)
 Other 18 (23.8%) 6 (13.6%) 24 (19.4%)
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sarcomas is more challenging in the distal than the 
proximal extremity. Therefore, this may represent a bias 
towards patients with more challenging tumours being 
referred to specialist centres providing ILP. A further 
limitation to this study is the inability to comment on 
the post-operative limb-function in each cohort, an addi-
tional important factor that may influence the choice of 
treatment strategy in these patients.
In the absence of any significant difference in out-
comes between these treatment strategies, the morbidity 
associated with their use becomes increasingly impor-
tant. Induction ILP carries the risks associated with an 
additional operation and short term toxicity associated 
with regional chemotherapy. That being said, the peri-
operative morbidity associated with ILP is generally very 
low. Severe regional toxicity following ILP is rare occur-
ring in 2–15% and the need for amputation even more 
so with rates of 0–2% [28]. The long-term complications 
from external beam radiotherapy, the technique used in 
the majority of patients in this study, are well documented 
Fig. 2 CONSORT diagram of the Standard and ILP cohorts
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[29]. However, during the period of this study, advances 
have been made in radiotherapy techniques. When given 
pre-operatively, the dose of radiotherapy may be reduced 
and the use of intensity-modulated radiotherapy, which 
is associated with lower toxicity rates, is becoming more 
widespread [15, 30]. Even so, the long-term sequelae of 
radiotherapy, including the risk of second malignancies, 
remain significant and are of particular importance in 
young patients [31].
Conclusion
Induction ILP followed by a wide resection provides an 
alternative treatment to standard therapy in the manage-
ment of locally advanced ESTS. Consideration should be 
given to induction ILP in young patients with large, high-
grade extremity sarcomas who would benefit most from 
avoiding radiotherapy.
Table 2 Post-operative outcomes in standard and ILP cohorts
Standard N = 80 ILP N = 44 p value
Complications
 All 25 (31%) 17 (39%) 0.43
 Wound infection 12 (15%) 7 (16%) 1.0
 Collection 13 (16%) 8 (18%) 0.81
 Amputation 0 (0%) 2 (5%) 0.12
Resection margin
 R0 65 (81%) 39 (89%) 0.32
 R1 15 (19%) 5 (11%)
Follow‑up, months
 Median 31 36 0.3373
 (Range) (4–194) (8–163)
Local recurrence 13 (16%) 5 (11%) 0.597
Local recurrence OR post‑operative amputation 13 (16%) 7 (16%) 1
Systemic recurrence 43 (54%) 23 (52%) 1
Fig. 3 Oncological outcomes for the ILP and Standard cohorts (logrank test was used to assess comparison)
Table 3 Multivariate cox proportional hazard analysis 
of factors effecting survival and recurrence of tumours 
by cohort
Local recurrence Systemic recurrence
HR (95% CI) p value HR (95% CI) p value
Standard 1.66 (0.64–4.27) 0.295 1.04 (0.63–1.73) 0.867
ILP 1 1
Increasing Age 1.04 (1.01–1.08) 0.02 1.02 (0.99–1.03) 0.78
1
Increasing size 0.951 (0.84–1.08) 0.44 1.04 (0.99–1.09) 0.98
1
R1 3.63 (1.36–9.69) 0.01 1.56 (0.85–2.89) 0.153
R0 1 1
Grade 3 1.74 (0.56–5.35) 0.33 0.91 (0.55–1.51) 0.704
Grade 2 1 1
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